organization · Reporting owner

AI Biotechnology LLC

Disclosed activity across 6 companies

Tapewire entity: 47387
SEC CIK: 0001942670

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Hemab Therapeutics Holdings, Inc.COAG · Entity 4476	10% owner	May 04, 2026	May 14, 2026
OnKure Therapeutics, Inc.OKUR · Entity 6550	10% owner	March 31, 2026	April 08, 2026
Upstream Bio, Inc.UPB · Entity 5743	10% owner	October 15, 2024	October 17, 2024
Verona Pharma plcVRNA · Entity 74409	10% owner	August 15, 2022	August 17, 2022
Yarrow Bioscience, Inc.VYNE · Entity 6871	10% owner	November 01, 2023	November 13, 2023
Zura Bio LtdZURA · Entity 5413	10% owner	February 26, 2026	March 02, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Hemab Therapeutics Holdings, Inc.

Report date May 04, 2026 · Filed May 14, 2026

Jointly reported with AI DEN-MAB LLC, Access Industries Holdings LLC, ACCESS INDUSTRIES MANAGEMENT, LLC, Blavatnik Len

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	4,876,344	Reported balance Holding disclosure · report date 2026-05-04 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 4,876,344 F1: The securities reported are held directly by AI DEN-MAB LLC ("AI DMAB") and may be deemed to be beneficially owned by AI Biotechnology LLC ("AIB"), Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because (i) Mr. Blavatnik controls AIM and AIH, (ii) AIM controls AIH and AIB, (iii) AIH owns all of the voting units of AIB, and (iv) AIB owns all of the voting units of AI DMAB. Each of AIH, AIB, AIM and Mr. Blavatnik, and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form.

Filing footnotes · ownership attribution and instrument terms

F1: The securities reported are held directly by AI DEN-MAB LLC ("AI DMAB") and may be deemed to be beneficially owned by AI Biotechnology LLC ("AIB"), Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because (i) Mr. Blavatnik controls AIM and AIH, (ii) AIM controls AIH and AIB, (iii) AIH owns all of the voting units of AIB, and (iv) AIB owns all of the voting units of AI DMAB. Each of AIH, AIB, AIM and Mr. Blavatnik, and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form.

OnKure Therapeutics, Inc.

Report date March 31, 2026 · Filed April 08, 2026

Jointly reported with Access Industries Holdings LLC, ACCESS INDUSTRIES MANAGEMENT, LLC, Blavatnik Len

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	Direct	3,998,332	Reported balance Holding disclosure · report date 2026-03-31 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 3,998,332 F2: The securities reported are held directly by AIB and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because (i) Mr. Blavatnik controls AIM and AIH, (ii) AIM controls AIH, and (iii) AIH owns all of the voting units of AIB. Each of AIH, AIM and Mr. Blavatnik, and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form.
Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Not disclosed	Reported balance Holding disclosure · report date 2026-03-31 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed F1: Each whole pre-funded warrant entitles AI Biotechnology LLC ("AIB") to purchase one share of Class A Common Stock at an exercise price equal to $0.0001 per share, and may be exercised at any time or times on or after the date of issuance, subject to the Beneficial Ownership Blocker (as defined herein). The pre-funded warrants are not exercisable to the extent that the aggregate number of Class A Common Stock beneficially owned by AIB immediately following such exercise would exceed 9.99% of the Class A Common Stock outstanding, as calculated under Rule 13d-3 of the Securities Exchange Act of 1934, as amended; provided, however, that AIB may increase or decrease the beneficial ownership limitation by giving notice to the Issuer (such notice not to be effective until the sixty-first day after the notice is delivered to the Issuer), but not to exceed any percentage in excess of 19.99% (such limitations, the "Beneficial Ownership Blocker"). F2: The securities reported are held directly by AIB and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because (i) Mr. Blavatnik controls AIM and AIH, (ii) AIM controls AIH, and (iii) AIH owns all of the voting units of AIB. Each of AIH, AIM and Mr. Blavatnik, and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form.

Filing footnotes · ownership attribution and instrument terms

F1: Each whole pre-funded warrant entitles AI Biotechnology LLC ("AIB") to purchase one share of Class A Common Stock at an exercise price equal to $0.0001 per share, and may be exercised at any time or times on or after the date of issuance, subject to the Beneficial Ownership Blocker (as defined herein). The pre-funded warrants are not exercisable to the extent that the aggregate number of Class A Common Stock beneficially owned by AIB immediately following such exercise would exceed 9.99% of the Class A Common Stock outstanding, as calculated under Rule 13d-3 of the Securities Exchange Act of 1934, as amended; provided, however, that AIB may increase or decrease the beneficial ownership limitation by giving notice to the Issuer (such notice not to be effective until the sixty-first day after the notice is delivered to the Issuer), but not to exceed any percentage in excess of 19.99% (such limitations, the "Beneficial Ownership Blocker").

F2: The securities reported are held directly by AIB and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because (i) Mr. Blavatnik controls AIM and AIH, (ii) AIM controls AIH, and (iii) AIH owns all of the voting units of AIB. Each of AIH, AIM and Mr. Blavatnik, and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form.

Upstream Bio, Inc.

Report date October 15, 2024 · Filed October 17, 2024

Jointly reported with AI Upstream LLC, Access Industries Holdings LLC, ACCESS INDUSTRIES MANAGEMENT, LLC, Blavatnik Len

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	5,494,410	Last balance in matching sequence After 2024-10-15 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2024-10-15 · Purchase · Acquired 1,175,000 · Balance 1,175,000 F2: The securities reported are held directly by AI Upstream LLC ("AI Upstream") and may be deemed to be beneficially owned by AI Biotechnology LLC ("AI Biotechnology"), Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because (i) Mr. Blavatnik controls AIM and AIH, (ii) AIM controls AIH, (iii) AIH owns all of the voting units of AI Biotechnology and (iv) AI Biotechnology owns all of the voting units of AI Upstream. Each of the reporting persons (other than AI Upstream) disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form. Row 2 · 2024-10-15 · Conversion · Acquired 3,147,000 · Balance 4,322,000 F1: Each share of the Issuer's Series A preferred stock and Series B preferred stock (collectively, the "Preferred Stock") converted into Common Stock on a 1.049-for-one basis upon closing of the Issuer's initial public offering without payment of consideration. The Preferred Stock had no expiration date. F2: The securities reported are held directly by AI Upstream LLC ("AI Upstream") and may be deemed to be beneficially owned by AI Biotechnology LLC ("AI Biotechnology"), Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because (i) Mr. Blavatnik controls AIM and AIH, (ii) AIM controls AIH, (iii) AIH owns all of the voting units of AI Biotechnology and (iv) AI Biotechnology owns all of the voting units of AI Upstream. Each of the reporting persons (other than AI Upstream) disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form. Row 3 · 2024-10-15 · Conversion · Acquired 1,172,410 · Balance 5,494,410 F1: Each share of the Issuer's Series A preferred stock and Series B preferred stock (collectively, the "Preferred Stock") converted into Common Stock on a 1.049-for-one basis upon closing of the Issuer's initial public offering without payment of consideration. The Preferred Stock had no expiration date. F2: The securities reported are held directly by AI Upstream LLC ("AI Upstream") and may be deemed to be beneficially owned by AI Biotechnology LLC ("AI Biotechnology"), Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because (i) Mr. Blavatnik controls AIM and AIH, (ii) AIM controls AIH, (iii) AIH owns all of the voting units of AI Biotechnology and (iv) AI Biotechnology owns all of the voting units of AI Upstream. Each of the reporting persons (other than AI Upstream) disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form.
Series A Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2024-10-15 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2024-10-15 · Conversion · Disposed 3,147,000 · Balance 0 F1: Each share of the Issuer's Series A preferred stock and Series B preferred stock (collectively, the "Preferred Stock") converted into Common Stock on a 1.049-for-one basis upon closing of the Issuer's initial public offering without payment of consideration. The Preferred Stock had no expiration date. F2: The securities reported are held directly by AI Upstream LLC ("AI Upstream") and may be deemed to be beneficially owned by AI Biotechnology LLC ("AI Biotechnology"), Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because (i) Mr. Blavatnik controls AIM and AIH, (ii) AIM controls AIH, (iii) AIH owns all of the voting units of AI Biotechnology and (iv) AI Biotechnology owns all of the voting units of AI Upstream. Each of the reporting persons (other than AI Upstream) disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form.
Series B Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2024-10-15 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2024-10-15 · Conversion · Disposed 1,172,410 · Balance 0 F1: Each share of the Issuer's Series A preferred stock and Series B preferred stock (collectively, the "Preferred Stock") converted into Common Stock on a 1.049-for-one basis upon closing of the Issuer's initial public offering without payment of consideration. The Preferred Stock had no expiration date. F2: The securities reported are held directly by AI Upstream LLC ("AI Upstream") and may be deemed to be beneficially owned by AI Biotechnology LLC ("AI Biotechnology"), Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because (i) Mr. Blavatnik controls AIM and AIH, (ii) AIM controls AIH, (iii) AIH owns all of the voting units of AI Biotechnology and (iv) AI Biotechnology owns all of the voting units of AI Upstream. Each of the reporting persons (other than AI Upstream) disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form.

Filing footnotes · ownership attribution and instrument terms

F1: Each share of the Issuer's Series A preferred stock and Series B preferred stock (collectively, the "Preferred Stock") converted into Common Stock on a 1.049-for-one basis upon closing of the Issuer's initial public offering without payment of consideration. The Preferred Stock had no expiration date.

F2: The securities reported are held directly by AI Upstream LLC ("AI Upstream") and may be deemed to be beneficially owned by AI Biotechnology LLC ("AI Biotechnology"), Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because (i) Mr. Blavatnik controls AIM and AIH, (ii) AIM controls AIH, (iii) AIH owns all of the voting units of AI Biotechnology and (iv) AI Biotechnology owns all of the voting units of AI Upstream. Each of the reporting persons (other than AI Upstream) disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form.

Verona Pharma plc

Report date August 15, 2022 · Filed August 17, 2022

Jointly reported with Access Industries Holdings LLC, ACCESS INDUSTRIES MANAGEMENT, LLC, Blavatnik Len

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Ordinary SharesSEC Table I · non-derivative	IndirectBy AI Biotechnology LLC	55,911,648	Reported balance After 2022-08-15 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2022-08-15 · Purchase · Acquired 4,800,000 · Balance 55,911,648 F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight ordinary shares of the Issuer. F2: The price reported represents the purchase price of the ADSs divided by eight. F3: The securities reported are held directly by AI Biotechnology LLC ("AIB") and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because Len Blavatnik controls AIM and controls a majority of the outstanding voting interests in AIH, AIM controls AIH, and AIH controls all of the outstanding voting interests in AIB. Each of the reporting persons (other than AIB) disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form.

Filing footnotes · ownership attribution and instrument terms

F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight ordinary shares of the Issuer.

F2: The price reported represents the purchase price of the ADSs divided by eight.

F3: The securities reported are held directly by AI Biotechnology LLC ("AIB") and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because Len Blavatnik controls AIM and controls a majority of the outstanding voting interests in AIH, AIM controls AIH, and AIH controls all of the outstanding voting interests in AIB. Each of the reporting persons (other than AIB) disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form.

Yarrow Bioscience, Inc.

Report date November 01, 2023 · Filed November 13, 2023

Jointly reported with Access Industries Holdings LLC, ACCESS INDUSTRIES MANAGEMENT, LLC, Blavatnik Len

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	1,116,585	Reported balance Holding disclosure · report date 2023-11-01 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 1,116,585 F1: The securities reported are held directly by AI Biotechnology LLC ("AI Biotechnology") and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because (i) Mr. Blavatnik controls AIM and AIH, (ii) AIM controls AIH, and (iii) AIH owns all of the voting units of AI Biotechnology. Each of the reporting persons (other than AI Biotechnology) disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form.
Warrant (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Not disclosed	Reported balance Holding disclosure · report date 2023-11-01 · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · Balance Not disclosed F2: Each pre-funded warrant is exercisable at any time after the date of issuance and the pre-funded warrants do not expire. The pre-funded warrants are not exercisable to the extent that the aggregate number of shares of Common Stock beneficially owned by AI Biotechnology immediately following such exercise would exceed 9.99%; provided, however, that AI Biotechnology may increase or decrease the beneficial ownership limitation by giving 60 days' notice to the Issuer, but not to exceed any percentage in excess of 19.99%.

Filing footnotes · ownership attribution and instrument terms

F1: The securities reported are held directly by AI Biotechnology LLC ("AI Biotechnology") and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because (i) Mr. Blavatnik controls AIM and AIH, (ii) AIM controls AIH, and (iii) AIH owns all of the voting units of AI Biotechnology. Each of the reporting persons (other than AI Biotechnology) disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form.

F2: Each pre-funded warrant is exercisable at any time after the date of issuance and the pre-funded warrants do not expire. The pre-funded warrants are not exercisable to the extent that the aggregate number of shares of Common Stock beneficially owned by AI Biotechnology immediately following such exercise would exceed 9.99%; provided, however, that AI Biotechnology may increase or decrease the beneficial ownership limitation by giving 60 days' notice to the Issuer, but not to exceed any percentage in excess of 19.99%.

Zura Bio Ltd

Report date February 26, 2026 · Filed March 02, 2026

Jointly reported with Access Industries Holdings LLC, ACCESS INDUSTRIES MANAGEMENT, LLC, Blavatnik Len

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Ordinary SharesSEC Table I · non-derivative	Direct	6,552,725	Reported balance After 2026-02-26 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2026-02-26 · Purchase · Acquired 2,000,000 · Balance 6,552,725 F1: Shares of Class A Ordinary Shares acquired pursuant to a registered offering of Class A Ordinary Shares by the Issuer. F2: The securities reported are held directly by AI Biotechnology LLC ("AIB") and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because (i) Mr. Blavatnik controls AIM and AIH, (ii) AIM controls AIH, and (iii) AIH owns all of the voting units of AIB. Each of AIH, AIM and Mr. Blavatnik, and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form.

Filing footnotes · ownership attribution and instrument terms

F1: Shares of Class A Ordinary Shares acquired pursuant to a registered offering of Class A Ordinary Shares by the Issuer.

F2: The securities reported are held directly by AI Biotechnology LLC ("AIB") and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because (i) Mr. Blavatnik controls AIM and AIH, (ii) AIM controls AIH, and (iii) AIH owns all of the voting units of AIB. Each of AIH, AIM and Mr. Blavatnik, and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 26, 2026 Filed Mar 2, 2026 22:55 UTC	Zura Bio Ltd ZURA · Entity 5413	PurchaseClass A Ordinary Shares	2,000,000	$6.25	$12,500,000.00	Disclosure SEC source: 0001193125-26-085900 · ownership.xml · nonDerivative · entry 1 AI Biotechnology LLC · CIK 0001942670 · 10% owner Access Industries Holdings LLC · CIK 0001391297 · 10% owner ACCESS INDUSTRIES MANAGEMENT, LLC · CIK 0001508226 · 10% owner Blavatnik Len · CIK 0001326628 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,552,725 F1 · kind: Shares of Class A Ordinary Shares acquired pursuant to a registered offering of Class A Ordinary Shares by the Issuer. F1 · shares: Shares of Class A Ordinary Shares acquired pursuant to a registered offering of Class A Ordinary Shares by the Issuer. F2 · ownership.direct: The securities reported are held directly by AI Biotechnology LLC ("AIB") and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because (i) Mr. Blavatnik controls AIM and AIH, (ii) AIM controls AIH, and (iii) AIH owns all of the voting units of AIB. Each of AIH, AIM and Mr. Blavatnik, and each of their affiliated entities and the officers, partners, members and managers thereof, disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form. Read SEC document
October 15, 2024 Filed Oct 17, 2024 16:05 UTC	Upstream Bio, Inc. UPB · Entity 5743	ConversionSeries B Convertible Preferred Stock · Derivative	1,172,410	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-115295 · ownership.xml · derivative · entry 5 AI Upstream LLC · CIK 0002039907 · 10% owner AI Biotechnology LLC · CIK 0001942670 · 10% owner Access Industries Holdings LLC · CIK 0001391297 · 10% owner ACCESS INDUSTRIES MANAGEMENT, LLC · CIK 0001508226 · 10% owner Blavatnik Len · CIK 0001326628 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,172,410 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A preferred stock and Series B preferred stock (collectively, the "Preferred Stock") converted into Common Stock on a 1.049-for-one basis upon closing of the Issuer's initial public offering without payment of consideration. The Preferred Stock had no expiration date. F1 · price: Each share of the Issuer's Series A preferred stock and Series B preferred stock (collectively, the "Preferred Stock") converted into Common Stock on a 1.049-for-one basis upon closing of the Issuer's initial public offering without payment of consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of the Issuer's Series A preferred stock and Series B preferred stock (collectively, the "Preferred Stock") converted into Common Stock on a 1.049-for-one basis upon closing of the Issuer's initial public offering without payment of consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of the Issuer's Series A preferred stock and Series B preferred stock (collectively, the "Preferred Stock") converted into Common Stock on a 1.049-for-one basis upon closing of the Issuer's initial public offering without payment of consideration. The Preferred Stock had no expiration date. F2 · ownership.direct: The securities reported are held directly by AI Upstream LLC ("AI Upstream") and may be deemed to be beneficially owned by AI Biotechnology LLC ("AI Biotechnology"), Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because (i) Mr. Blavatnik controls AIM and AIH, (ii) AIM controls AIH, (iii) AIH owns all of the voting units of AI Biotechnology and (iv) AI Biotechnology owns all of the voting units of AI Upstream. Each of the reporting persons (other than AI Upstream) disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form. Read SEC document
October 15, 2024 Filed Oct 17, 2024 16:05 UTC	Upstream Bio, Inc. UPB · Entity 5743	ConversionSeries A Convertible Preferred Stock · Derivative	3,147,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-115295 · ownership.xml · derivative · entry 4 AI Upstream LLC · CIK 0002039907 · 10% owner AI Biotechnology LLC · CIK 0001942670 · 10% owner Access Industries Holdings LLC · CIK 0001391297 · 10% owner ACCESS INDUSTRIES MANAGEMENT, LLC · CIK 0001508226 · 10% owner Blavatnik Len · CIK 0001326628 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,147,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each share of the Issuer's Series A preferred stock and Series B preferred stock (collectively, the "Preferred Stock") converted into Common Stock on a 1.049-for-one basis upon closing of the Issuer's initial public offering without payment of consideration. The Preferred Stock had no expiration date. F1 · price: Each share of the Issuer's Series A preferred stock and Series B preferred stock (collectively, the "Preferred Stock") converted into Common Stock on a 1.049-for-one basis upon closing of the Issuer's initial public offering without payment of consideration. The Preferred Stock had no expiration date. F1 · derivative.exercise_date: Each share of the Issuer's Series A preferred stock and Series B preferred stock (collectively, the "Preferred Stock") converted into Common Stock on a 1.049-for-one basis upon closing of the Issuer's initial public offering without payment of consideration. The Preferred Stock had no expiration date. F1 · derivative.expiration_date: Each share of the Issuer's Series A preferred stock and Series B preferred stock (collectively, the "Preferred Stock") converted into Common Stock on a 1.049-for-one basis upon closing of the Issuer's initial public offering without payment of consideration. The Preferred Stock had no expiration date. F2 · ownership.direct: The securities reported are held directly by AI Upstream LLC ("AI Upstream") and may be deemed to be beneficially owned by AI Biotechnology LLC ("AI Biotechnology"), Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because (i) Mr. Blavatnik controls AIM and AIH, (ii) AIM controls AIH, (iii) AIH owns all of the voting units of AI Biotechnology and (iv) AI Biotechnology owns all of the voting units of AI Upstream. Each of the reporting persons (other than AI Upstream) disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form. Read SEC document
October 15, 2024 Filed Oct 17, 2024 16:05 UTC	Upstream Bio, Inc. UPB · Entity 5743	ConversionCommon Stock	1,172,410	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-115295 · ownership.xml · nonDerivative · entry 3 AI Upstream LLC · CIK 0002039907 · 10% owner AI Biotechnology LLC · CIK 0001942670 · 10% owner Access Industries Holdings LLC · CIK 0001391297 · 10% owner ACCESS INDUSTRIES MANAGEMENT, LLC · CIK 0001508226 · 10% owner Blavatnik Len · CIK 0001326628 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 5,494,410 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's Series A preferred stock and Series B preferred stock (collectively, the "Preferred Stock") converted into Common Stock on a 1.049-for-one basis upon closing of the Issuer's initial public offering without payment of consideration. The Preferred Stock had no expiration date. F2 · ownership.direct: The securities reported are held directly by AI Upstream LLC ("AI Upstream") and may be deemed to be beneficially owned by AI Biotechnology LLC ("AI Biotechnology"), Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because (i) Mr. Blavatnik controls AIM and AIH, (ii) AIM controls AIH, (iii) AIH owns all of the voting units of AI Biotechnology and (iv) AI Biotechnology owns all of the voting units of AI Upstream. Each of the reporting persons (other than AI Upstream) disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form. Read SEC document
October 15, 2024 Filed Oct 17, 2024 16:05 UTC	Upstream Bio, Inc. UPB · Entity 5743	ConversionCommon Stock	3,147,000	Not disclosed	Not disclosed	Disclosure SEC source: 0000950170-24-115295 · ownership.xml · nonDerivative · entry 2 AI Upstream LLC · CIK 0002039907 · 10% owner AI Biotechnology LLC · CIK 0001942670 · 10% owner Access Industries Holdings LLC · CIK 0001391297 · 10% owner ACCESS INDUSTRIES MANAGEMENT, LLC · CIK 0001508226 · 10% owner Blavatnik Len · CIK 0001326628 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,322,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each share of the Issuer's Series A preferred stock and Series B preferred stock (collectively, the "Preferred Stock") converted into Common Stock on a 1.049-for-one basis upon closing of the Issuer's initial public offering without payment of consideration. The Preferred Stock had no expiration date. F2 · ownership.direct: The securities reported are held directly by AI Upstream LLC ("AI Upstream") and may be deemed to be beneficially owned by AI Biotechnology LLC ("AI Biotechnology"), Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because (i) Mr. Blavatnik controls AIM and AIH, (ii) AIM controls AIH, (iii) AIH owns all of the voting units of AI Biotechnology and (iv) AI Biotechnology owns all of the voting units of AI Upstream. Each of the reporting persons (other than AI Upstream) disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form. Read SEC document
October 15, 2024 Filed Oct 17, 2024 16:05 UTC	Upstream Bio, Inc. UPB · Entity 5743	PurchaseCommon Stock	1,175,000	$17.00	$19,975,000.00	Disclosure SEC source: 0000950170-24-115295 · ownership.xml · nonDerivative · entry 1 AI Upstream LLC · CIK 0002039907 · 10% owner AI Biotechnology LLC · CIK 0001942670 · 10% owner Access Industries Holdings LLC · CIK 0001391297 · 10% owner ACCESS INDUSTRIES MANAGEMENT, LLC · CIK 0001508226 · 10% owner Blavatnik Len · CIK 0001326628 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,175,000 F2 · ownership.direct: The securities reported are held directly by AI Upstream LLC ("AI Upstream") and may be deemed to be beneficially owned by AI Biotechnology LLC ("AI Biotechnology"), Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because (i) Mr. Blavatnik controls AIM and AIH, (ii) AIM controls AIH, (iii) AIH owns all of the voting units of AI Biotechnology and (iv) AI Biotechnology owns all of the voting units of AI Upstream. Each of the reporting persons (other than AI Upstream) disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form. Read SEC document
August 15, 2022 Filed Aug 17, 2022 20:03 UTC	Verona Pharma plc VRNA · Entity 74409	PurchaseOrdinary Shares	4,800,000	$1.31	$6,300,000.00	Disclosure SEC source: 0001209191-22-046214 · doc4.xml · nonDerivative · entry 1 Access Industries Holdings LLC · CIK 0001391297 · 10% owner AI Biotechnology LLC · CIK 0001942670 · 10% owner ACCESS INDUSTRIES MANAGEMENT, LLC · CIK 0001508226 · 10% owner Blavatnik Len · CIK 0001326628 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By AI Biotechnology LLC Disclosed balance after: 55,911,648 F1 · security: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight ordinary shares of the Issuer. F2 · price: The price reported represents the purchase price of the ADSs divided by eight. F3 · ownership.direct: The securities reported are held directly by AI Biotechnology LLC ("AIB") and may be deemed to be beneficially owned by Access Industries Holdings LLC ("AIH"), Access Industries Management, LLC ("AIM") and Len Blavatnik because Len Blavatnik controls AIM and controls a majority of the outstanding voting interests in AIH, AIM controls AIH, and AIH controls all of the outstanding voting interests in AIB. Each of the reporting persons (other than AIB) disclaims beneficial ownership of these securities, except to the extent of its or his pecuniary interest therein, and this form shall not be construed as an admission that any such reporting person is the beneficial owner of any of the securities reported on this form. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.